Literature DB >> 36029406

Histone Modifications in Neurological Disorders.

Bradley J Smith1, Victor Corasolla Carregari2.   

Abstract

Post-translational modifications (PTMs) have a strong impact on many proteins across all kingdoms of life, affecting multiple functional and chemical properties of their protein recipients. With increasing knowledge about their functions, targets, and biological effects, dysregulations in PTMs have been implicated in various dysfunctions and diseases. One such target are histones, which compose the majority of the protein component of chromatin and the modulation of the 30+ PTMs that are known to affect them can have profound effects on chromatin state, gene expression, and DNA repair. In this review, the histone targets of PTMs are compiled in the context of neurological disorders, highlighting their specific biological roles and any previously implicated dysregulations in several classes of brain disease. Better understanding the pathogenic dysregulations of PTMs in such disorders can help to better understand their causes, as well as open doors to new possibilities for biomarkers and therapeutic targets.
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Histones; Neurodevelopmental disorders; Post-translational modifications; Psychiatric disorders

Mesh:

Substances:

Year:  2022        PMID: 36029406     DOI: 10.1007/978-3-031-05460-0_7

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   3.650


  59 in total

1.  Allelic imbalance of expression and epigenetic regulation within the alpha-synuclein wild-type and p.Ala53Thr alleles in Parkinson disease.

Authors:  Gerassimos E Voutsinas; Eleana F Stavrou; Gerassimos Karousos; Aggeliki Dasoula; Adamantia Papachatzopoulou; Maria Syrrou; Annemieke J M H Verkerk; Peter van der Spek; George P Patrinos; Reinhard Stöger; Aglaia Athanassiadou
Journal:  Hum Mutat       Date:  2010-06       Impact factor: 4.878

2.  Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity.

Authors:  Eirene Kontopoulos; Jeffrey D Parvin; Mel B Feany
Journal:  Hum Mol Genet       Date:  2006-09-07       Impact factor: 6.150

3.  Histone Deacetylase Inhibitors Protect Against Pyruvate Dehydrogenase Dysfunction in Huntington's Disease.

Authors:  Luana Naia; Teresa Cunha-Oliveira; Joana Rodrigues; Tatiana R Rosenstock; Ana Oliveira; Márcio Ribeiro; Catarina Carmo; Sofia I Oliveira-Sousa; Ana I Duarte; Michael R Hayden; A Cristina Rego
Journal:  J Neurosci       Date:  2017-01-25       Impact factor: 6.167

4.  Increased acetyl and total histone levels in post-mortem Alzheimer's disease brain.

Authors:  Pritika J Narayan; Claire Lill; Richard Faull; Maurice A Curtis; Mike Dragunow
Journal:  Neurobiol Dis       Date:  2014-12-05       Impact factor: 5.996

Review 5.  Epigenetic regulation in neurodevelopment and neurodegenerative diseases.

Authors:  K Gapp; B T Woldemichael; J Bohacek; I M Mansuy
Journal:  Neuroscience       Date:  2012-12-19       Impact factor: 3.590

6.  Striatal histone modifications in models of levodopa-induced dyskinesia.

Authors:  Anthony P Nicholas; Farah D Lubin; Penelope J Hallett; Padmapriya Vattem; Paula Ravenscroft; Erwan Bezard; Shaobo Zhou; Susan H Fox; Jonathan M Brotchie; J David Sweatt; David G Standaert
Journal:  J Neurochem       Date:  2008-07-01       Impact factor: 5.372

7.  Epigenetic modifications in frontal cortex from Alzheimer's disease and bipolar disorder patients.

Authors:  J S Rao; V L Keleshian; S Klein; S I Rapoport
Journal:  Transl Psychiatry       Date:  2012-07-03       Impact factor: 6.222

Review 8.  The class II histone deacetylases as therapeutic targets for Parkinson's disease.

Authors:  Martina Mazzocchi; Louise M Collins; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Neuronal Signal       Date:  2020-06-09

9.  The histone modification H3K4me3 is altered at the ANK1 locus in Alzheimer's disease brain.

Authors:  Adam R Smith; Rebecca G Smith; Ruby Macdonald; Sarah J Marzi; Joe Burrage; Claire Troakes; Safa Al-Sarraj; Jonathan Mill; Katie Lunnon
Journal:  Future Sci OA       Date:  2021-02-09

10.  A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.

Authors:  Nuria Suelves; Lucy Kirkham-McCarthy; Robert S Lahue; Silvia Ginés
Journal:  Sci Rep       Date:  2017-07-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.